
Commentary|Videos|February 3, 2025
Clinical Implications of FDA Approval of Luspatercept for Anemia in ESA-Naive Lower-Risk MDS
Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, on the FDA approval of luspatercept in ESA-naive lower-risk MDS.
Advertisement
Episodes in this series

Advertisement
Related to this article

The FDA approved iberdomide-based therapy for relapsed myeloma, rejected a neuroendocrine tumor therapy, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Iberdomide Plus Daratumumab/Dexamethasone for R/R Myeloma
2
FDA Grants Fast Track Designation to Spevatamig in Advanced and Metastatic Biliary Tract Carcinoma
3
Dr Viansone on De-Escalating Chemotherapy Type and Duration in HER2-Positive Breast Cancer
4
Novel Approaches for Hematocrit Control Are Driving Research in Polycythemia Vera
5

